NEW YORK, March 10, 2021 /PRNewswire/ — DemeRx IB, Inc. (DemeRx), an atai Life Sciences (atai) platform company focused on developing ibogaine for the treatment of opioid use disorder (OUD), today announced the company has approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to commence subject enrollment in a Phase 1/2a clinical trial of ibogaine HCl (DMX-1002).


Previous articleNova Mentis Upgrades U.S. Listing to the OTCQB Venture Market
Next articleAion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers)